Evidence map›Paper›PMID 35687356›Full record

ArticleDrug testing and analysis2022

Characterization of new psychoactive substances by integrating benchtop NMR to multi-technique databases.

Thomas Castaing-Cordier, Alejandra Benavides Restrepo, Damien Dubois, Virginie Ladroue, Fabrice Besacier, Audrey Buleté, Céline Charvoz, Anais Goupille, Denis Jacquemin, Patrick Giraudeau and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Drug testing and analysis, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Thomas Castaing-CordierNantes Université, CNRS, CEISAM, UMR 6230, Nantes, France.
Alejandra Benavides RestrepoNantes Université, CNRS, CEISAM, UMR 6230, Nantes, France.
Damien DuboisLaboratoire de Police Scientifique de Lyon, Service National de Police Scientifique, Ecully, France.
Virginie LadroueLaboratoire de Police Scientifique de Lyon, Service National de Police Scientifique, Ecully, France.
Fabrice BesacierSous-direction de la stratégie de l'innovation et du pilotage, Service National de Police Scientifique, Ecully, France.ORCID https://orcid.org/0000-0003-4990-8901
Audrey BuletéLaboratoire de Police Scientifique de Lyon, Service National de Police Scientifique, Ecully, France.
Céline CharvozLaboratoire de Police Scientifique de Lyon, Service National de Police Scientifique, Ecully, France.
Anais GoupilleNantes Université, CNRS, CEISAM, UMR 6230, Nantes, France.
Denis JacqueminNantes Université, CNRS, CEISAM, UMR 6230, Nantes, France.
Patrick GiraudeauNantes Université, CNRS, CEISAM, UMR 6230, Nantes, France.
Jonathan FarjonNantes Université, CNRS, CEISAM, UMR 6230, Nantes, France.ORCID https://orcid.org/0000-0003-0707-2026
Centre National de la Recherche Scientifique · FRInstitut National de Police Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New psychoactive substances (NPS) have become a serious threat for public health due to their ability to be sold in the street or on internet. NPS are either derived from commercial drugs which are misused (recreational rather than medical use) or whose structure is slightly modified. To regulate NPS, it is essential to accurately characterize them, either to recognize molecules that were previously identified or to quickly elucidate the structure of unknown ones. Most approaches rely on the determination of the exact mass obtained by high-resolution mass spectrometry requiring expensive equipment. This motivated us to develop a workflow in which the elucidation is assisted with databases and does not need the exact mass. This workflow combines 1D and 2D NMR measurements performed on a benchtop spectrometer with IR spectroscopy, for creating a multi-technique database to characterize pure and mixed NPS. The experimental database was created with 57 entries mostly coming from seizures, mainly cathinones, cannabinoids, amphetamines, arylcyclohexylamines, and fentanyl. A blind validation of the workflow was carried out on a set of six unknown seizures. In the first three cases, AF, AB-FUBINACA, and a mixture of 2C-I and 2C-E could be straightforwardly identified with the help of their reference spectra in the database. The two next samples were elucidated for the first time with the help of the database to reveal NEK and MPHP substances. Finally, a precise quantification of each characterized NPS was obtained in order to track NPS trafficking networks.

Indexed as

CannabinoidsIllicit DrugsAmphetaminesHumansPsychotropic DrugsSeizuresAmphetaminesCannabinoidsIllicit DrugsPsychotropic DrugsbenchtopdatabaseIRNMRNPS

Identifiers

PMID35687356
PMCPMC9545896
OpenAlexW4281897997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.